Minerva Neurosciences Inc
NERV
NASDAQ
Biotechnology
$4.58
USD
+0.66 (+16.84%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $187.17M
Volume 340.0K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-394.35M
TTM
-3611.7%
YoY
Operating Cash Flow
$-26.17M
TTM
-67.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 2.1 | 1.9 | 2.8 | 11.4 | 3.5 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 3.4 | 2.8 | 5.0 | 16.7 | 10.6 |
Operating Income | -3.4 | -2.8 | -5.0 | -16.7 | -10.6 |
EBITDA | -3.4 | -2.8 | -5.0 | -16.7 | -10.6 |
Other Income / Expense | -0.0 | -0.0 | -279.2 | -109.4 | 27.5 |
Total Other Income / Expense | 0.1 | 0.1 | -278.7 | -108.7 | 28.1 |
Income Before Income Taxes | -3.3 | -2.7 | -283.7 | -125.4 | 17.5 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -3.3 | -2.7 | -283.7 | -125.4 | 17.5 |
Consolidated Net Income / Loss | -3.3 | -2.7 | -283.7 | -125.4 | 17.5 |
Net Income Attributable to Common Shareholders | -3.3 | -2.7 | -283.7 | -125.4 | 16.6 |
Basic EPS | -$0.43 | -$0.36 | -$25.45 | -$2.86 | $0.36 |
Diluted EPS | -$0.43 | -$0.36 | -$25.45 | -$2.86 | -$0.14 |
Basic Shares Outstanding | 7.6M | 7.6M | 11.1M | 43.9M | 46.6M |
Diluted Shares Outstanding | 7.6M | 7.6M | 11.1M | 43.9M | 79.1M |